Pharmaceutical Technology

FEBRUARY 3, 2023

Since HIV integrates with the DNA, eliminating the virus from the body is very difficult, explains David Montefiori, PhD, director of the Laboratory for AIDS Vaccine Research and Development at Duke University in Durham, North Carolina. The failure of several late-stage trials highlights the challenging nature of HIV vaccine development.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

pharmaphorum

MAY 11, 2021

Flagship Pioneering, the VC fund run by Moderna’s co-founder Noubar Afeyan has launched a new biotech Laronde , with an ambitious plan to create a new class of drugs based on Endless RNA. The technology is designed to replace antibodies, which have become standard therapy in many diseases but are complicated and expensive to manufacture.

RNA 98

RNA Drugs Protein Immune Response 98

Roots Analysis

OCTOBER 22, 2023

RNA therapeutics are a novel class of biopharmaceuticals that harness the power of RNA molecules for the treatment and prevention of a wide range of disorders, including oncological, and genetic disorders as well as infectious diseases. Non-coding RNAs include antisense oligonucleotides (ASOs) and RNA aptamers.

RNA 40

RNA Protein Genetics Gene Expression 40

Pharmaceutical Technology

MARCH 9, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. It focuses on the discovery and development of RNA-targeted drugs.

RNA 130

RNA DNA Antibody Production 130

The Pharma Data

APRIL 30, 2021

Under the multi-year agreement, AbbVie will utilize Caribou’s next-generation Cas12a CRISPR hybrid RNA-DNA genome editing and cell therapy technologies to research and develop two new CAR-T cell therapies directed to targets specified by AbbVie. AbbVie and Caribou Biosciences, Inc., Full-Year 2021 Outlook. to $7.47.

Botox 40

Botox Production Development Cosmetics 40

Pharmaceutical Technology

MAY 8, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. These viruses carry the genetic information to synthesise an RNA-dependent RNA polymerase.

RNA 240

RNA Genetics Vaccination Vaccine 240

Pharmaceutical Technology

JUNE 4, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Genetics 130

Genetics Gene Expression DNA Antibody 130

Pharmaceutical Technology

FEBRUARY 14, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

In-Vivo 130

In-Vivo DNA Antibody Gene 130

XTalks

NOVEMBER 7, 2022

Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. Another method to isolate CTCs is by antibody targeting of white blood cells for removal, followed by collection of untagged CTCs.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

XTalks

OCTOBER 26, 2023

The Flu versus COVID-19: Virology and Vaccines SARS-CoV-2 versus Influenza Virology Viruses contain genetic material that can either be RNA or DNA. Both influenza and SARS-CoV-2 have RNA as their genetic material. An RNA genome enables the genetic material to mutate more rapidly. For COVID, it is much the same case.

Vaccination 105

Vaccination Vaccine RNA Manufacturing 105

XTalks

MARCH 10, 2021

While molecular PCR-based tests remain the gold standard for the detection of SARS-CoV-2 viral RNA, rapid antigen tests are useful for screening purposes. Adding to the testing repertoire is the first T cell-based test that can detect previous infection, akin to antibody tests. 1. First T-Cell Test from Adaptive Biotechnologies.

Protein 98

Protein RNA Antibody Production 98

pharmaphorum

OCTOBER 12, 2022

The payload, Del Bourgo tell us, is the therapeutic DNA or RNA sequence that will cure or fix damaged cells. Whitelab Genomics operates a proprietary AI platform to accelerate the development of DNA and RNA-based therapies, also known as genomic therapies. This is just the beginning; the potential is enormous,” he says.

Genome 105

Genome Genomics Medicine Development 105

Roots Analysis

SEPTEMBER 9, 2024

The rising demand for protein therapeutics, such as monoclonal antibodies and vaccines , is driving advancements in protein expression technology to ensure efficient and scalable production. This process initially involves transcription of DNA to messenger RNA (mRNA). The mRNA is then translated into to form functional proteins.

Protein 40

Protein Gene Production DNA 40

XTalks

NOVEMBER 30, 2023

Over 26 weeks of Sunlenca combined with other antiretroviral drugs, 81 percent of participants achieved HIV RNA suppression, reaching levels low enough to be considered undetectable. The noteworthy candidate, EBT-101, is designed to eliminate HIV proviral DNA using CRISPR-Cas9 along with two guide RNAs (gRNAs).

FDA Approval 111

FDA Approval Gene Therapy Gene Clinical Trials 111

The Pharma Data

AUGUST 3, 2021

Revenue growth was 12 percent when excluding effects of 2020 COVID-related stocking patterns, revenue from COVID-19 antibodies and recent business development. million in the second quarter of 2021 for its COVID-19 antibodies. million of revenue in the second quarter of 2021 from COVID-19 antibodies, $170.0 Excluding $148.9

Antibody 52

Antibody Sales Development Production 52

The Pharma Data

DECEMBER 3, 2020

For example, “Viral antigens and antibodies (typically IgM and IgG) become detectable at different periods during infection…and the detection time…depends on several parameters, such as viral features, individual patient variability and the applied test.” Other techniques are primed to replace it.

RNA 52

RNA Protein DNA Antibody 52

Roots Analysis

DECEMBER 12, 2023

As a result, innovators came up with the idea of magic bullets, antibody drug conjugates (ADCs). It is comprised of three components, namely antibody, drug and linker. The antibody is conjugated to the drug via a linker molecule. The antibody is conjugated to the drug via a linker molecule. Components of an ADC?

Antibody 40

Antibody Drugs Manufacturing Development 40

Roots Analysis

AUGUST 15, 2023

Biomanufacturing utilizing cell free systems is an emerging area of research that enables the synthesis of different biomolecules, such as cytotoxic proteins, fusion proteins, post translationally modified proteins, antibodies, enzymes, vaccines and other complex proteins, without the use of living cells.

Protein 52

Protein In-Vitro Production Reagent 52

Roots Analysis

OCTOBER 16, 2023

Biopharmaceutical filtration is a critical step in the production of biopharmaceuticals, including proteins, antibodies, and vaccines. These filters do not deteriorate sensitive biomolecules such as antibody, vaccines and recombinant proteins.

Bacteria 40

Bacteria Production Protein Contamination 40

pharmaphorum

DECEMBER 21, 2020

Their technology is based on synthetic messenger RNA – short for ribose nucleic acid – which is a short transcript of a longer DNA code. The body produces antibodies against the protein, which neutralise the virus in the event of an infection.

Vaccination 111

Vaccination Vaccine Doctors Doctor 111

The Pharma Data

DECEMBER 27, 2020

Vir Biotechnology and GlaxoSmithKline dosed the first patient in a new sub-trial of a Phase III study of monoclonal antibody VIR-7831 for hospitalized adults with COVID-19. Galidesivir is a broad-spectrum antiviral, an adenosine nucleoside analog that blocks viral RNA polymerase. Here’s a look. COVID-19-Related. Non-COVID-19-Related.

Trials 52

Trials Antibody Gene Therapy Gene 52

XTalks

AUGUST 2, 2023

2) Darzalex (daratumumab) Darzalex is a targeted monoclonal antibody that slows or stops the progression of multiple myeloma (a blood cancer) by binding to the CD38 protein on multiple myeloma cells. The monoclonal antibody targets CD20, a protein found on the surface of B lymphocytes (B cells). billion in 2022, a 32.44

Sales 98

Sales Manufacturing FDA Approval Life Science 98

WCG Clinical

MAY 28, 2024

B cells are needed in order to mount new antibody responses against vaccines and infections, so a lack of B cells can potentially result in immune deficiency and an increased risk of infection. If circulating antibody levels become too low, they may be supplemented with immunoglobulin therapy.

In-Vivo 40

In-Vivo Clinical Trials Clinical Trials FDA Approval 40

Roots Analysis

MAY 21, 2024

Gene Therapies: LNPs have the ability to effectively deliver nucleic acids, including small interfering RNA (siRNA), messenger RNA (mRNA), and plasmid DNA to the target cells. Further, they have been extensively utilized in the development of mRNA vaccines for COVID-19.

Drug Delivery 40

Drug Delivery Drugs Gene Therapy Bioavailability 40

XTalks

DECEMBER 24, 2020

Most antibody drugs and vaccines have been developed to target parts of the spike protein. These include remdesivir, baricitinib, dexamethasone and three antibody drugs. Antibody drugs were also developed as targeted COVID-19 treatments. Drug Approvals.

Life Science 111

Life Science Vaccination Vaccine Gene 111

XTalks

SEPTEMBER 14, 2020

Moderna, for one, recently reported positive results in older adults between 56 and 71, as well as those 71 years of age and older, who reportedly mounted levels of neutralizing antibodies against the SARS-CoV-2 virus after two doses of its vaccine that were comparable to those seen in younger adults. Johnson & Johnson’s COVID-19 Vaccine.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92